UniQure Net Profit Margin 2013-2022 | QURE
UniQure net profit margin from 2013 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
| UniQure Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2022-09-30 |
$0.06B |
$-0.13B |
-206.56% |
| 2022-06-30 |
$0.06B |
$-0.12B |
-185.48% |
| 2022-03-31 |
$0.53B |
$0.32B |
61.41% |
| 2021-12-31 |
$0.52B |
$0.33B |
62.60% |
| 2021-09-30 |
$0.50B |
$0.32B |
63.80% |
| 2021-06-30 |
$0.50B |
$0.30B |
60.40% |
| 2021-03-31 |
$0.04B |
$-0.14B |
-368.42% |
| 2020-12-31 |
$0.04B |
$-0.13B |
-331.58% |
| 2020-09-30 |
$0.01B |
$-0.17B |
-2371.43% |
| 2020-06-30 |
$0.01B |
$-0.14B |
-2266.67% |
| 2020-03-31 |
$0.01B |
$-0.12B |
-2066.67% |
| 2019-12-31 |
$0.01B |
$-0.12B |
-1771.43% |
| 2019-09-30 |
$0.01B |
$-0.11B |
-1750.00% |
| 2019-06-30 |
$0.01B |
$-0.10B |
-1287.50% |
| 2019-03-31 |
$0.01B |
$-0.09B |
-1033.33% |
| 2018-12-31 |
$0.01B |
$-0.08B |
-763.64% |
| 2018-09-30 |
$0.01B |
$-0.09B |
-741.67% |
| 2018-06-30 |
$0.01B |
$-0.08B |
-700.00% |
| 2018-03-31 |
$0.01B |
$-0.08B |
-592.31% |
| 2017-12-31 |
$0.01B |
$-0.08B |
-600.00% |
| 2017-09-30 |
$0.02B |
$-0.07B |
-347.37% |
| 2017-06-30 |
$0.02B |
$-0.07B |
-295.83% |
| 2017-03-31 |
$0.02B |
$-0.07B |
-308.70% |
| 2016-12-31 |
$0.02B |
$-0.07B |
-304.17% |
| 2016-09-30 |
$0.02B |
$-0.08B |
-405.26% |
| 2016-06-30 |
$0.02B |
$-0.09B |
-568.75% |
| 2016-03-31 |
$0.01B |
$-0.09B |
-650.00% |
| 2015-12-31 |
$0.01B |
$-0.08B |
-754.55% |
| 2015-09-30 |
$0.01B |
$-0.06B |
-711.11% |
| 2015-06-30 |
$0.01B |
$-0.05B |
-766.67% |
| 2015-03-31 |
$0.01B |
$-0.04B |
-740.00% |
| 2014-12-31 |
$0.01B |
$-0.03B |
-566.67% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.907B |
$0.106B |
|
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
|
